Top-Line Growth and Revenue Beat
Q1 revenue of $5.1B, +2.9% organic YoY, came in at the high end of guidance; product and service revenues showed strong reported growth of +7.3% and +7.5% respectively.
GE Healthcare Technologies Inc
· GEHC
April 29th, 2026
Summary
- Earnings Call Date:
- 2026-04-29
- Change Since:
- +9.08%
- Next Earnings Date:
- 2026-08-05
Earnings Call Sentiment
NeutralThe call balanced encouraging top-line execution, product/regulatory milestones, a record backlog and strategic progress (Flyrcado ramp, Photonova approvals, Intelerad acquisition, organizational realignment) against meaningful near-term profitability headwinds from supplier issues, tariffs and material inflation (~$250M gross impact). Management maintained revenue guidance but prudently reduced earnings guidance and emphasized mitigation actions whose benefits are weighted to the back half of 2026. The tone was confident on medium-term growth while realistic on near-term margin pressure.
Company Guidance
GE HealthCare maintained revenue guidance of 3%–4% organic sales growth (Q2 also guided 3%–4%), expects an approximate 100-basis-point FX tailwind to revenue, and set full-year adjusted EBIT margin at 15.4%–15.7% (up ~10–40 bps year‑over‑year) with adjusted EPS now $4.80–$5.00 (≈5%–9% growth YoY, and a low‑single‑digit EPS decline expected in Q2); management called out a gross inflation headwind of roughly $250 million (~$0.43/share) — driven by about $100M memory chips, $100M oil/freight and ~$50M metals/other — of which they expect to offset more than half via price and cost actions (they reduced EPS by $0.15 for the remaining inflation effect), expect tariffs to be lower than 2025 (Q1 contained the largest tariff hit and adjusted EPS included ~ $0.16 of tariff impact), and now forecast free cash flow of approximately $1.6 billion (supported by a 1.07x book‑to‑bill and a record $21.8 billion backlog).
Record Backlog and Healthy Orders
Record backlog of $21.8B, up $1.2B YoY; orders grew +1.1% and company delivered a solid book-to-bill of 1.07x, supporting the maintained full-year organic sales guidance of +3% to +4%.
Strong Segment Performers
Pharmaceutical Diagnostics delivered robust organic growth of +9.7% YoY; Imaging grew +3.8% organic YoY and Advanced Visualization Solutions grew +4.4% organic YoY with AVS EBIT margin up ~120 bps YoY.
Services and Recurring Revenue Strength
High-margin services business performed well with reported service revenue growth of +7.5%, contributing to recurring revenue and cash generation.
Product and Regulatory Milestones
Regulatory clearances for Photonova Spectra (Photon-counting CT) in the U.S. and Japan and multiple FDA clearances in MR (including new 3T, reduced helium platform and AI workflow); majority of NPIs moved from clearance to early commercial orders.
Radiopharmaceutical Momentum (Flyrcado)
Flyrcado ramped meaningfully with nearly +80% increase in doses since late January and ~390 doses delivered in the week ended April 17; company reaffirmed medium-term target of $500M+ annual revenue for the molecule by 2028.
Strategic M&A and Portfolio Moves
Completed Intelerad acquisition in Q1 to strengthen cloud/enterprise imaging capabilities; announced organizational realignment combining Imaging and ABS into a new Advanced Imaging Solutions segment to accelerate commercialization and R&D alignment.
Cash & Capital Deployment
Q1 free cash flow of $112M (up $13M YoY); repaid $500M of debt and repurchased ~ $100M of shares while maintaining dividend; updated FY free cash flow target ~ $1.6B.
Operator
Good day, and thank you for standing by. Welcome to the GE HealthCare First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. Now it's my pleasure to hand the conference over to Carolynne Borders. Please proceed.
Carolynne Borders
Thanks, operator. Good morning, and welcome to GE HealthCare's First Quarter 2026 Earnings Call. I'm joined by our President and CEO, Peter Arduini; and Vice President and CFO, Jay Saccaro. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties.
With that, I'll turn the call over to Peter.
Peter Arduini
Thanks, Carolynne. Good morning, and thank you for joining us. Let me start with our performance in the first quarter of 2026. We were pleased with the top line growth that came in at the high end of our expectations driven by our pharmaceutical diagnostics, advanced visualization solutions and imaging businesses. We also had strong services growth in the quarter. This all reflects disciplined commercial execution and accelerated customer adoption of new products designed to help clinicians enhance diagnostic accuracy and guide more precision treatment decisions across disease states. As we think about the ...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free